News

Single molecule imaging allows scientists to understand the function of enzymes with unprecedented detail and to utilise them as reagents in novel single molecule assays. Here, we explore the unique value that this offers.

VIEW PDF →

SMi is delighted to be short listed as a finalist in the category of Best Emerging Pharma Company/Start Up.

VIEW ARTICLE →

Knight Optical describes how they worked with SMi’s engineers to develop custom optics for volume manufacture.

VIEW ARTICLE →

SMi becomes ISO 13485 certified following its recent audit by the British Standards Institution.

VIEW PDF →

Being able to detect analytes is a critical aspect of drug discovery and diagnosis. Here we show how single molecule counting can increase assay sensitivity.

VIEW PDF →

SMi is delighted to continue expanding its portfolio with the granting of another patent.

VIEW PDF →

SMi Systems is developing a commercial analytics platform that automates single-molecule detection and analysis. Here we describe why single-molecule measurements are likely to become the go-to approach when developing novel drugs and vaccines.

VIEW PDF →

SMi Systems is developing a commercial analytics platform that automates single-molecule detection and analysis. Here we describe why single-molecule measurements are likely to become the go-to approach when developing novel drugs and vaccines.

VIEW PDF →

SMi has been contracted to develop another Quality Control assay that enables single molecule detection of contaminating infectious particles.

VIEW PDF →

SMi expands its IP portfolio further by receiving a Notice of Allowance from the US Patent and Trademark Office for its high throughput single molecule imaging platform.

VIEW PDF →

Global health expert in vaccines, diagnostics and infectious disease prevention, advises on the application of SMi’s technology to vaccine development and diagnostic testing.

VIEW PDF →

Albert Vilella highlights that SMi’s platform can be applied to a wide range of biomolecules, including proteins, nucleic acids, and small molecules, making it valuable in various fields, from drug discovery to diagnostics.

VIEW ARTICLE →

SMi describes the differences between the regulatory considerations for research use only (RUO) products and those destined for in vitro diagnostics (IVD) use, and consider how risk management can be simultaneously applied.

VIEW PDF →

Single molecule imaging could be transformative for cancer biomarker detection. Here the MDC reports on foundational data from its collaboration with SMi.

VIEW POSTER →

Batalas features how their internal audit training course helped SMi work towards ISO 13485:2016 Quality Management System certification.

VIEW ARTICLE →

SMi has worked with ProPharma to build an ISO 13485 Quality Management System that ensures compliance to rigorous medical device standards. ProPharma Group describe what made this a huge success.

VIEW ARTICLE →

SMi Systems is developing an analytics platform that utilises advanced optics and algorithms to automate detection of single molecules within a sample. We provide an overview of computational methods and why they are so important.

VIEW PDF →

Top-ranked life sciences analyst joins as SMi enters commercialisation with an instrument ready for early access customers and a focus shifting to precision engineered consumables.

VIEW PDF →

Single molecule analysis could transform drug development. Both the speed and quality of this process will be dramatically improved when there is a commercial single molecule platform that can accurately measure drug properties.

VIEW PDF →

SMi Systems has successfully passed the Stage 1 audit for ISO 13485 certification conducted by the British Standards Institution.

VIEW PDF →

SMi Systems is developing a revolutionary benchtop instrument that probes drug interactions at single-molecule resolution. This is the story of how the groundbreaking innovation was inspired.

VIEW SMI SHORTS →

Accurate detection and quantification are the cornerstones of scientific and clinical research. Only the highest quality data enables informed decisions, but achieving this can conflict with time and financial constraints.

VIEW SMI SHORTS →

SMi reveals the foundational work that proved our capability to perform high throughput multiplexing at single molecule resolution.

VIEW PDF →

SMi is delighted to continue expanding its portfolio with the granting of a second patent.

VIEW PDF →

Using its single molecule detection and quantification capabilities, SMi has been contracted to develop a novel quality control assay for biologics production.

VIEW PDF →

SMi announces its appointment of two new research scientists to expand its laboratory talent.

VIEW PDF →

SMi is delighted to win first place in the Best New Business category.

VIEW ARTICLE →

The super-resolution optical technology will accelerate discovery in biomedical research and transform in vitro diagnostics.

VIEW PDF →

SMi is delighted to be named as a finalist for the Best New Business award.  The ceremony is due to take place on 28th September 2023.

VIEW ARTICLE →

Medicines Discovery Catapult and SMi’s CEO describe what has made their partnership so successful.

VIEW VIDEO →

Medicines Discovery Catapult features the success of SMi’s partnerships to develop diagnostics for cancer and infectious disease.

VIEW ARTICLE →

Investment enables development of revolutionary multi-omic platform using super-resolution imaging technology for earlier disease detection and accelerated discovery of therapeutics.

VIEW PDF →

The University of Cambridge has released a press article detailing SMi’s revolutionary diagnostic technology.

VIEW ARTICLE →

SMi has been shortlisted for two awards, ‘The One to Watch’ and ‘Medtech Company of the Year.’ The ceremony is to be held on 18th May 2023.

VIEW ARTICLE →

Medicines Discovery Catapult and SMi secure funding to validate cancer biomarker technology.

VIEW ARTICLE →

Following the award of a £1.9m grant from Innovate UK in 2021, SMi has again been successful in competing for a highly prestigious award for innovative research.

VIEW PDF →

SMi has completed its first formal usability tests at the UK’s Medical Devices Testing and Evaluation Centre, located at the University Hospitals Birmingham NHS Foundation Trust.

VIEW PDF →

SMi has achieved a great deal since starting its operations at the end of 2021. In addition to employing its full complement of scientists, engineers and regulatory specialists, SMi has also opened both its UK offices and US-based laboratories.

VIEW PDF →

Funding unlocks strategic partnerships with the Medicines Discovery Catapult, University of Cambridge, and National Physical Laboratory.

VIEW PDF →